BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.75 USD
-0.07 (-9.05%)
Updated May 31, 2024 04:00 PM ET
After-Market: $0.74 -0.01 (-0.75%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
BioLineRx Ltd. [BLRX]
Reports for Purchase
Showing records 101 - 120 ( 203 total )
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 and Keytruda Team Up for an Intriguing Match; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
ASH Data Drives Continued Momentum for ''8040
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Investor Day; ''8040''s Oncology Potential and Mozobil Differentiation
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
3Q15 Results; ''8040 Continues to be Center of Focus
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
After the Wait, ''8040 Delivers; More at ASH; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Healthcare - Focusing on Value Creating Catalysts for Our CoverageThis report contains brief updates on the following: ADRO, AGTC, APHB, APTO, ARGS, BLRX, CFRX, CNCE, CYTK, CYTX, IMNP, PTN, STML, T.TST. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
2Q15 Results; ''8040 Main Driver Backed by Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
BL-8040 Program Marches On With New Study; AML PhII Topline Data Coming
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
Bellerophon Gets Dinged; Focus Remains on ''8040; Target Lowered to $7
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: BioLineRx Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: BioLineRx Ltd.
Industry: Medical - Drugs
PRESERVATION - Data Soon; Should Serve as Proxy for Upcoming U.S. Study
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J